Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 17/20 | 0.56 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | LYN | P07948 | 1/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.52 |
| ▸ | FLT4 | P35916 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | BLK | P51451 | 1/20 | 0.52 |
| ▸ | BMX | P51813 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.52 |
| ▸ | TAOK2 | Q9UL54 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19499707 | 0.90 | FGFR1 (0.60) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL19499699 | 0.90 | FGFR1 (0.48) | FGFR1FGFR2FGFR4 | |
| SCHEMBL19499688 | 0.88 | FGFR1 (0.49) | FGFR1FGFR2FGFR4 | |
| SCHEMBL19499695 | 0.87 | FGFR1 (0.47) | FGFR1FGFR2FGFR4 | |
| SCHEMBL19508236 | 0.85 | FGFR1 (0.61) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993041 | 0.84 | FGFR1 (0.78) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL17925409 | 0.81 | FGFR1 (0.52) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL15413205 | 0.81 | FGFR1 (0.68) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL19470190 | 0.80 | FGFR1 (0.52) | FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL16993420 | 0.80 | FGFR1 (0.78) | FGFR1FGFR2CSF1RLYNFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | NEWAVE PHARMACEUTICAL INC. | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | FGFR4, FGFR2, FGFR3 | FGFR1 4/4885FGFR2 2/4885CSF1R 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.